Inhibition of TORC1 and downstream S6K with the rapalog everolimus derepresses levels of insulin receptor substrate (IRS)-1 expression leading to activation of PI3K and phosphorylation of AKT at S473 in both cancer cell lines and tumors of patients [14-16]. The gene discussed is PIK3CD; the disease is cancer.